White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome
Mohamed A, do Campo J, Del Fante P, Kwiatek R, Calhoun V, Shan Z. White-matter changes associated with a synergetic treatment for myalgic encephalomyelitis/chronic fatigue syndrome. Fatigue Biomedicine Health & Behavior 2024, ahead-of-print: 1-11. DOI: 10.1080/21641846.2024.2367921.Peer-Reviewed Original ResearchMyalgic encephalomyelitis/chronic fatigue syndromeLow-dose naltrexoneFatigue syndromeWhite-matter tractsPre-treatment baselineDebilitating chronic illnessDeficit symptomsME/CFS patientsDiffusion-weighted imaging dataReducing depressionTreating ME/CFSSymptom improvementFractional anisotropyOff-label treatmentWhite-matter changesNaltrexoneNICE guidelinesPost-treatmentSymptomsME/CFSNeuroimaging characteristicsClinical measuresChronic illnessControl groupRandomized controlled trials